Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Expected Admission 21 July 2023.
Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission was previously meant to be today and is now TBC.
Metals One Plc, a company focusing on acquiring natural resources projects with a focus on critical battery metals, including nickel, lithium, cobalt and copper intends to join the AIM Market. The Company will have interests in the Paltamo and Rautavaara projects (nickel, copper, zinc) in Finland (together the Black Schist Project) and the Brownfield Råna Nickel project in Norway (Brownfield Rana Project). These projects represent opportunities to develop deposits of scale, in stable jurisdictions, well situated to supply fastest growing European electric vehicle and energy storage markets. The Company aims to raise £2.5m at 5 pence per share with an anticipated market cap of £10.72m. Expected Admission date is 27 July 2023.
Praetura Growth VCT plc, a newly established VCT announces its intention to float on the Main Market of the London Stock Exchange. The Company will provide growth funding to scalable businesses predominantly based in the North of England, across a range of sectors including technology and healthcare. The Company will be managed by Praetura Ventures Limited, a venture capital and EIS business associated with the wider Praetura Group, a Manchester based venture capital investor and small business lender. The Company is targeting to raise £10m at 1 pence per share, via an offer for subscription. The Directors will have the option to utilise an over-allotment facility that will allow the Company to issue a further 10m Ordinary Shares under the Offer.
Ariana Resources 2.425p £27.8m (AAU.L)
The mineral exploration and development company with gold mining interests in Europe, provides an update on Venus Minerals Limited, in which Ariana has a 58% shareholding. Venus has re-engaged with its advisers and is now actively proceeding with its intention to seek admission to AIM. Venus is proposing to raise up to £3m from new investors, following which Ariana will hold approximately 35% of Venus. Venus is progressing towards an IPO during Q3 2023, with marketing to commence imminently. The IPO will enable Venus to undertake a further exploration programme on its portfolio of 100%-owned copper/gold assets in Cyprus.
Fonix Mobile 210p £209.5m (FNX.L)
The mobile payments and messaging provider, provides a trading update for the year ended 30 June 2023. Revenue and profit have continued to grow and ended the year marginally ahead of market expectations. Gross profit in the Year grew by 14.4% to £15.1m (FY22: £13.2m). Adjusted EBITDA grew by 12.6% to £11.6m (FY22: £10.3m). Fonix continues to generate strong underlying cash flows and intends to pay an increased final dividend in November 2023, in line with the Company's progressive dividend policy to pay out at least 75% of adjusted earnings per share. With high levels of repeating revenue, a strong run-rate entering the new financial year, recent tier 1 wins in the UK and Ireland, the Board continues to be confident in the growth potential for Fonix going into FY24 and beyond.
Gateley Holdings 149.5p £189.3 (GTLY.L)
The professional services group announces the acquisition of Richard Julian and Associates Limited, trading as RJA Consultants (RJA), for total consideration of not more than £6m, including earnout based on the EBITDA achieved in each 12-month period expiring 31 March 2024 and 31 March 2025. In the financial year ended 31 March 2023, RJA generated revenue of c.£3.9m, corporatised profit before tax of c.£0.8m and organic revenue growth of 65% against the prior year. RJA is a chartered surveying practice, providing quantity surveying and project management services across a variety of construction sectors. It specialises in the affordable housing sector, a resilient sector underpinned by high levels of grants to support delivery of the Government's housing targets.
Jadestone Energy 33p £178.5m (JSE.L)
The independent oil and gas production company focused on the Asia-Pacific region, provides a trading update for the half-year ending 30 June 2023. H1 2023 production was c.12,300 boe/d, down 22% year-on-year, primarily reflecting the shut-in of Montara production until late-March 2023 and lower production at the PenMal assets largely due to natural decline. Average oil price realisation was US$86.2, down 21% year-on-year, reflecting the decline in Brent prices. The Group reaffirmed its production, underlying operating cost and capital expenditure guidance for 2023 remains unchanged. The Akatara gas development project in Indonesia is 42% complete and remains on plan, budget and schedule for first gas in H1 2024. East Belumut infill drilling campaign offshore Malaysia is on schedule to commence in August 2023.
Jubilee Metals Group 7.65p £209.5m (JLP.L)
The platinum focused mining and exploration company with operations in Africa, publishes its unaudited Operational Update for the 12 months to 30 June 2023 (FY23). PGM operations recorded 42 474 oz, up 2% and exceeding full year guidance of 38 000 oz. Chrome production was up 7% to 1 289 890 tonnes, exceeding full year guidance of 1 200 000 tonnes. Copper production was 2923 tonnes up 29%,marginally below revised guidance of 3000 tonnes primarily due to previously announced power and water disruptions in Zambia. FY24 outlook is as follows: PGM production stepping up to 42 000 oz. Chrome production is expected to reach a new record of 1 450 000 tonnes, following completion of new 360 000 tonne per annum chrome concentrate facility announced in June 2023. Targeted copper output is to double to 5 850 tonnes of copper, thanks to the upgrade to the Roan concentrator expected over the next 12 weeks.
Metals Exploration 2.15p £45.1m (MTL.L)
The gold producer in the Philippines announces its quarterly results for Q2 2023, with record half-year and quarterly gold sales: H1 2023 46,186 ounces sold at an average realised gold price of US$1,939 per ounce (H1 2022: 30,676 ounces at an average US$1,878 per ounce). H1 2023 free cash flow was US$41.9m (H1 2022: US$13.6m). Net debt as at 30 June 2023 was US$48.3m (31 March 2023: US$69.0m). Operations in H1 2023 have exceeded expectations with head grade, tonnes milled and recovery rates all above forecast. Although the head grade for H2 2023 is forecast to drop, the Company has updated its FY2023 production guidance as follows: gold production forecast: 78,000-81,000 ounces (previous guidance: 68,000-72,000 ounces). FY 2023 updated AISC forecast is US$1,120-US$1,200 per ounce (previous guidance: US$1,250-US$1,300 per ounce).
M.P. Evans Group 673p £361.8m (MPE.L)
The producer of sustainable Indonesian palm oil, announces its crop and production information for the six months ended 30 June 2023. The total crop of fresh fruit bunches (ffb) processed by the Group in the first half of 2023 was 408,100 tonnes, 2% higher year-on-year. Crude palm oil (CPO) production was 166,200 tonnes, up 3% year-on-year. The Group anticipates higher cropping levels as it moves into the second half of the year. The Group realised an average CPO price at mill gate of US$755 per tonne compared with US$1,035 in H1 2022, a decrease of 27%. Prices for PK averaged US$410 per tonne (mill gate), 51% lower than the US$830 per tonne in 2022.
Nexteq 147.5p £98.1m (NXQ.L)
The technology solutions provider to customers in selected industrial markets, provides a trading update for the six months ended 30 June 2023. Group revenue in H1 23 grew 6% to $56.3m. The Group continued to see a recovery in gross margins through H1 23 due to a greater proportion of Densitron sales from higher margin Broadcast products and the continued easing in global supply chains. Net cash position as at 30 June 2023 was $18.5m, up 43% from 31 December 2022 ($12.9m), as working capital levels reduced in line with easing supply chains. The improved operating margins seen in H1 23 are expected to result in full year adjusted profit before tax in line with market expectations.
Pharos Energy 23.1p £99.3m (PHAR.L)
The independent energy company issues a trading update in advance of its interim results on 13 September 2023. Group working interest H1 production was 6,915 boepd net. Group working interest 2023 production guidance of 6,050 – 7,500 boepd net remains unchanged from the preliminary results announcement on 22 March 2023. Group revenue for H1 2023 was $86m, without realised hedging gains or losses. Cash balances at 30 June 2023 was c.$36m and net debt was c.$16m (down from $28.9m at 31 December 2022).
Verici Dx 12.25p £20.9m (VRCI.L)
The developer of advanced clinical diagnostics for organ transplant, announces that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including California, with the Company laboratory now fully accredited in a total of 49 states. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
